Answers are grounded in this paper and cite their sources.
Prospective validation identifies EMG and NfL as key criteria for differentiating PLS and ALS, suggesting improved trial enrollment strategies.
In our population, reclassification of PLS to ALS occurred at a low frequency at 1 year follow-up (7.1%). Baseline NfL was the strongest predictor in differentiating UMN dominant ALS from PLS at 1-year follow-up. Based on our data, we propose EMG and NfL criteria for enrollment in future PLS trials.
No takes yet. Share an insight, caveat, or question.
Sorenson et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: